CancerIQ: democratizing access to precision medicine cancer care
CancerIQ is democratizing access to precision medicine cancer care. We make hereditary cancer risk assessment faster and cheaper, so that patients can get direct access to care, so that more providers can screen for genetic risk factors, and so that specialists can scale care to patients at lower costs.For our poster presentation, we will demonstrate our platform and discuss our unique approach to patient-centered design. In order to ensure that our product resonates with patients, we partnered with ePatient designer and founder of Brave Bosom, Andrea Downing.
The NIH has outlined a new strategic vision for the 21st Century, which will shift the focus of research toward medicine that is Predictive, Personalized, Preemptive, and Participatory (NIH 4P’s). This strategic vision has great potential to be realized within cancer care through use of genomic technologies, which are rapidly becoming faster, cheaper, and more scalable. Yet, great barriers to widespread adoption of genomic-based cancer prevention strategies include limited knowledge in a rapidly evolving field, a growing shortage of cancer specialists and genetic counselors, complicated and fragmented care delivery systems, and mounting pressures to reduce cost. Despite lowered costs of DNA sequencing and increasingly powerful informatics tools, practitioners are unable to meet the needs of millions of patients newly diagnosed with cancer globally, and unable to serve family members at risk. To solve these problems, there is an urgent need to develop innovative health information technology (HIT) to scale evidence-based practice in cancer risk assessment and prevention.The CancerIQ platform addresses these key barriers. Our minimum viable product, the CancerIQ Practice AssistantTM, improves knowledge by providing access to a curated library of evidence and online access to experts, to streamline workflow through data capture and analysis tools, and to reduce costs through improved care coordination and utilization. Our product was developed by a team of leading practitioners with expertise in cancer genetic risk assessment within the global Clinical Cancer Genetics Community of Practice (CCGCoP), an ongoing educational initiative led by City of Hope and University of Chicago. Our goal is to close the gap between evidence-based theory and everyday clinical practice.